United States Brent Oil Fund LP vs BioNTech SE - ADR — how do they compare? United States Brent Oil Fund LP trades at $50.73, while BioNTech SE - ADR trades at $93.16 (market cap $23.31B). The key difference: United States Brent Oil Fund LP is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNO | BNTX | |
|---|---|---|
Sector | Commodities - Energy | Health |
52-Week High | $60.13 | $119.34 |
52-Week Low | $27.20 | $83.89 |
Market Cap | — | $23.31B |
Enterprise Value | — | $6.60B |
Signals from Pluang's Aura AI — not financial advice
BNO is trading at $50.505, up 0.79% with a bullish technical outlook supported by moving averages. The oil market faces significant supply disruptions from Middle East tensions, particularly the Strait of Hormuz closure, creating volatility. Recent OPEC demand forecast cuts contrast with supply constraints, creating a complex fundamental backdrop for oil-related securities.
The stock presents opportunity from ongoing supply constraints but faces headwinds from demand destruction and inventory builds. Key risks include geopolitical resolution and demand volatility. Technical momentum remains positive near-term, but fundamental uncertainties require careful monitoring of oil market developments.
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Trailing returns across standard periods
BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.
Read more on BNO →BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →